Paget's Disease of Bone: Causes, Symptoms, Diagnosis, and Treatment

What Is Paget's Disease of Bone?

Paget's disease of bone (osteitis deformans) is a focal disorder of bone remodeling driven by dysregulated osteoclast activity. Affected sites cycle through exaggerated resorption, chaotic new bone deposition, and eventual sclerosis, producing bone that is enlarged but mechanically inferior. The condition is site-specific rather than systemic, which separates it sharply from osteoporosis.

Named after Sir James Paget, who described it in 1877, the disease affects an estimated 2 to 3% of people over age 55 in Europe, North America, and Australia, with declining prevalence over recent decades for reasons that remain under investigation [1]. Men are affected slightly more often than women at a ratio of approximately 1.4:1 [2]. Most patients are asymptomatic and identified incidentally on imaging or through elevated serum alkaline phosphatase (ALP) found during routine blood work [3].

The underlying biology centers on osteoclasts that are both larger than normal (containing up to 100 nuclei rather than the standard 3, 5) and substantially more active [4]. This hyperstimulated resorption triggers compensatory osteoblast activity, but the new bone laid down is woven rather than lamellar, creating a mosaic pattern on histology and structurally compromised cortex. Blood flow to affected bone increases markedly, and in extensive disease the cardiovascular load has been documented to raise cardiac output by as much as 15% [5].

How Paget's Disease Differs From Osteoporosis and Osteopenia

Paget's disease and osteoporosis are frequently confused by patients, and distinguishing them matters because their treatments differ entirely. Osteoporosis is a systemic reduction in bone mineral density (BMD) affecting the entire skeleton, diagnosed by dual-energy X-ray absorptiometry (DXA) when the T-score reaches -2.5 or below [6]. Osteopenia sits between -1.0 and -2.5. Neither osteoporosis nor osteopenia involves the focal enlargement and chaotic architecture characteristic of Paget's.

Paget's disease does not lower BMD on DXA. Pagetic bone often reads as denser than surrounding bone because its disorganized matrix traps more mineral per unit area, even though its mechanical quality is poor. A patient can have a normal or elevated DXA T-score in a pagetic vertebra and still be at high fracture risk from that vertebra [7].

Postmenopausal bone loss is the dominant driver of osteoporosis in women. Estrogen ordinarily suppresses RANKL-mediated osteoclast activation; after menopause, RANKL signaling increases and bone resorption accelerates [8]. The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68% over 36 months in postmenopausal women with osteoporosis, confirming the RANKL pathway as a therapeutic target [9]. Paget's osteoclasts are also RANKL-responsive, which is why bisphosphonates and denosumab affect both conditions, but the clinical context and monitoring strategy differ completely.

Male osteoporosis is underdiagnosed. Approximately 2 million American men have osteoporosis and another 12 million have osteopenia, according to the National Osteoporosis Foundation [10]. Men with Paget's disease carry risk for both conditions simultaneously and require DXA screening of non-pagetic skeletal sites to assess systemic BMD independently of pagetic lesions [11].

Causes and Risk Factors

The etiology of Paget's disease involves a combination of genetic predisposition and, most likely, environmental triggers. Paramyxovirus exposure was proposed as a trigger decades ago, but that hypothesis has not been confirmed in controlled studies [12].

Mutations in the SQSTM1 gene (sequestosome-1, encoding p62) are the strongest identified genetic risk factor, present in roughly 25 to 40% of familial cases and 5 to 10% of apparently sporadic cases [13]. The p62 protein regulates NF-kB signaling in osteoclasts; loss-of-function variants lead to abnormal osteoclast differentiation. First-degree relatives of affected individuals carry a 7-fold elevated risk of developing the disease [14].

Additional susceptibility loci identified through genome-wide association studies include CSF1, OPTN, TM7SF4, and RIN3 [15]. The declining prevalence since the 1970s suggests a cohort effect tied to an environmental exposure that has diminished, though no specific pathogen or toxin has been confirmed [1].

Risk is higher in people of British, European, or Australian ancestry. It is uncommon in Asia and sub-Saharan Africa, pointing toward a gene-environment interaction rather than purely genetic causation [2].

Symptoms and Clinical Presentation

Roughly 70% of people with Paget's disease are asymptomatic at diagnosis [3]. When symptoms appear, they depend on which bones are involved and what complications have developed.

Bone pain is the most common symptom, described as a deep, aching discomfort that is present at rest and worsens at night. It arises from periosteal stretching, increased vascularity, and microfractures [16]. Patients sometimes confuse this with arthritis, particularly when the pelvis or spine is involved.

Skull involvement causes characteristic frontal bossing and, as the base of skull thickens, progressive sensorineural or conductive hearing loss in up to 37% of patients with skull disease [17]. Cranial nerve compression can produce facial palsy, tinnitus, or vertigo. Spinal Paget's disease can narrow the spinal canal and cause neurologic symptoms from cord or nerve root compression [16].

Long bone deformity is visible in advanced untibial or femoral disease. The tibia takes on a characteristic anterior bow (the "sabre tibia"). Femoral disease produces a lateral bow. Stress fractures, called "banana fractures," propagate across the convex cortex [18].

Osteosarcoma occurs in less than 1% of cases but carries a poor prognosis with 5-year survival below 10% [19]. New, rapidly worsening pain in a previously stable pagetic site warrants immediate imaging. High-output cardiac failure from extensive pagetic vascularity is a rare but life-threatening complication [5].

Diagnosis: Labs, Imaging, and Bone Biopsy

Diagnosis integrates biochemical markers with characteristic imaging findings. Histology is reserved for cases where malignant transformation is suspected.

Serum alkaline phosphatase (ALP) is the standard biochemical marker. Total ALP is elevated in proportion to pagetic bone surface area; a normal ALP in the absence of liver disease makes active, extensive Paget's unlikely [20]. Bone-specific ALP and serum P1NP provide greater specificity and are preferred when liver disease confounds total ALP interpretation [21].

Radiography remains the first imaging step. Pagetic bone shows cortical thickening, trabecular coarsening, bone enlargement, and characteristic lytic lesions (the "blade of grass" or "flame-shaped" lytic front in long bones) [22]. X-rays of the skull may show osteoporosis circumscripta, a well-defined lytic area in the frontal or occipital bone.

Bone scintigraphy (technetium-99m) maps the extent of skeletal involvement and identifies clinically silent sites. The scan shows intense focal tracer uptake at pagetic lesions [23]. It is useful at baseline to document disease extent, though it is not required at every follow-up visit.

CT and MRI are used when neurologic symptoms suggest cord compression or when osteosarcoma is a concern. MRI detects soft tissue extension and marrow signal changes not visible on plain film [19].

Bone biopsy is only indicated when imaging and biochemistry cannot exclude malignancy. The histologic mosaic pattern (irregular cement lines, woven bone, large multinucleated osteoclasts) is pathognomonic but rarely needed for diagnosis in straightforward presentations [4].

Treatment: Bisphosphonates and Beyond

The goal of treatment is biochemical remission, defined as normalization of ALP, and symptom control. The Endocrine Society clinical practice guideline published in 2014 recommends treatment for all patients with active disease (elevated ALP) affecting sites at risk for complications, including weight-bearing bones, skull, spine, and bone adjacent to major joints [24].

Zoledronic Acid (First-Line)

Zoledronic acid 5 mg given as a single 15-minute IV infusion is the most effective agent available. The PRISM-EZ trial (N=272) showed that a single dose achieved ALP normalization in 89% of patients at 6 months, compared with 58% for oral risedronate 30 mg daily for 2 months [25]. The biochemical response is durable: at 6.5 years of follow-up, 57% of zoledronic acid patients remained in remission without retreatment, versus 10% of risedronate patients [26].

Transient post-infusion flu-like symptoms (acute phase reaction) occur in up to 30% of first-time recipients and typically resolve within 3 days [25]. Pre-hydration and acetaminophen 1 g every 6 hours for 24 to 48 hours reduce severity. Hypocalcemia is a risk in vitamin D-deficient patients; supplement with at least 1 to 000 IU vitamin D daily and 1 to 200 mg calcium daily before infusion [24].

Oral Bisphosphonates (Alternatives)

Risedronate 30 mg daily for 2 months and alendronate 40 mg daily for 6 months are acceptable alternatives when IV administration is not feasible [24]. Both achieve ALP normalization in roughly 50 to 70% of patients but require strict dosing protocols (taken on an empty stomach with 240 mL water, 30 minutes before food) to achieve adequate absorption [27].

Pamidronate 60 mg IV over 2 to 4 hours repeated at intervals is an older option still used when zoledronic acid is unavailable or not tolerated [28].

Monitoring After Treatment

ALP should be rechecked at 3 to 6 months after completing a course. If ALP returns to the upper limit of normal or the pre-treatment elevation recurs by more than 25% above the post-treatment nadir, retreatment is indicated [24]. Imaging is not repeated on a fixed schedule but is prompted by new symptoms, worsening pain, or ALP re-elevation. Annual DXA of non-pagetic sites is reasonable in patients who also meet criteria for osteoporosis screening, particularly postmenopausal women and men over 70 [11].

Calcitonin (Historical)

Salmon calcitonin by subcutaneous injection was used before bisphosphonates became available. Response rates are substantially lower, duration of effect shorter, and long-term use carries a small increased risk of malignancy identified by the European Medicines Agency in 2012 [29]. Calcitonin is no longer recommended as primary therapy for Paget's disease.

Surgery

Orthopedic surgery addresses complications rather than the underlying disease. Indications include joint replacement for pagetic arthritis, osteotomy for severe long bone deformity causing functional impairment, and spinal decompression for neurologic compromise [30]. Pre-operative bisphosphonate therapy to reduce bone vascularity and intraoperative blood loss is standard practice before elective procedures on pagetic bone.

Paget's Disease in the Context of Postmenopausal and Male Bone Loss

A patient with Paget's disease may simultaneously carry systemic risk for osteoporosis, and the two problems require parallel management tracks.

Postmenopausal women lose approximately 2 to 3% of trabecular bone per year in the first 5 to 10 years after menopause due to estrogen withdrawal [8]. The FLEX trial extension of the FIT study showed that after 5 years of alendronate, women with femoral neck T-score above -2.5 could safely discontinue therapy without significant fracture increase over the subsequent 5 years, while those with T-score below -2.5 benefited from continuation [31]. Women with Paget's disease involving the spine or hip cannot rely on T-score alone to guide decisions in pagetic sites; non-pagetic skeletal sites must be used for that calculation.

Men over 70 with Paget's disease should be evaluated for secondary causes of bone loss including hypogonadism, vitamin D deficiency, and glucocorticoid use. Testosterone deficiency is the male analog of estrogen deficiency in postmenopausal women and produces a similar increase in RANKL-driven osteoclast activity [32]. The Osteoporotic Fractures in Men (MrOS) study (N=5,994) confirmed that low serum estradiol (below 16 pg/mL) in men predicted hip fracture risk independently of BMD [33]. This matters for pagetic men because low estradiol may accelerate bone loss at non-pagetic sites even while pagetic sites appear radiographically dense.

The following decision framework integrates Paget's-specific management with systemic bone health assessment:

1. Confirm Paget's diagnosis (ALP + imaging).
2. Map disease extent with bone scintigraphy.
3. Treat active disease with zoledronic acid 5 mg IV if any high-risk site is involved.
4. Assess systemic BMD via DXA at non-pagetic lumbar vertebrae and contralateral hip.
5. Screen for secondary osteoporosis causes: 25-OH vitamin D, testosterone (men), calcium, creatinine, PTH.
6. Initiate osteoporosis therapy independently if T-score meets criteria at non-pagetic sites.
7. Recheck ALP at 3 to 6 months; schedule DXA repeat in 1 to 2 years at non-pagetic sites.

Nutritional and Lifestyle Factors

Adequate calcium and vitamin D are required regardless of whether the primary issue is Paget's disease, osteoporosis, or both. The Institute of Medicine recommends 1 to 200 mg elemental calcium daily for adults over 50 and 800, 1 to 000 IU vitamin D3 daily to maintain serum 25-OH vitamin D above 20 ng/mL [34]. Patients receiving bisphosphonate therapy for either condition should reach these targets before and during treatment to avoid hypocalcemia.

Weight-bearing exercise preserves BMD at non-pagetic sites and is safe in Paget's disease unless active lytic lesions in weight-bearing bones create fracture risk [35]. Walking, resistance training, and balance exercises reduce fall risk, which is particularly relevant because Paget's disease can cause gait abnormalities and hearing loss that independently increase fall frequency.

Smoking reduces BMD and impairs bone healing. A meta-analysis of 59 studies (N=40,753) found that current smokers had a relative risk of 1.25 for hip fracture compared with non-smokers [36]. Patients with Paget's disease who smoke carry compounded fracture risk from pagetic bone fragility and systemic BMD reduction.

Excessive alcohol consumption suppresses osteoblast function and is associated with a 1.38-fold increased hip fracture risk per meta-analysis data [37]. Limiting intake to no more than 1, 2 standard drinks per day is a reasonable and evidence-consistent recommendation.

Complications and Long-Term Outlook

With modern bisphosphonate therapy, most patients achieve durable biochemical remission and avoid major complications. Hearing loss, once established, does not reliably reverse after treatment, making early diagnosis in patients with skull involvement particularly valuable [17]. The Endocrine Society guideline states: "Treatment of Paget's disease is recommended in patients with active disease as evidenced by elevated serum ALP who are at risk for future complications" [24].

Fracture through pagetic bone is a surgical emergency because the high vascularity of active lesions causes substantial intraoperative bleeding, and the abnormal architecture complicates internal fixation [30]. Pre-treating with zoledronic acid 6 to 8 weeks before planned orthopedic procedures reduces blood loss and may improve fixation outcomes [28].

Osteosarcoma transformation, while rare, requires prompt recognition. The American Cancer Society notes a median survival of 8 months for Paget's-associated osteosarcoma, making early biopsy of suspicious lesions time-sensitive [19]. Any patient reporting sudden escalation of bone pain at a known pagetic site, especially with soft tissue swelling or rapid ALP rise, should have MRI within days rather than weeks.

Quality of life improves measurably after effective treatment. The PRISM trial quality-of-life substudy found no significant difference in symptom scores between intensive bisphosphonate therapy and symptomatic-only treatment at 3-year follow-up, suggesting that biochemical remission alone does not always translate to faster symptom relief, and that analgesic and physical therapy support remains important alongside disease-modifying drugs [38].